CRISPR Therapeutics (NASDAQ:CRSP) Rating Increased to Sell at StockNews.com

CRISPR Therapeutics (NASDAQ:CRSP) was upgraded by investment analysts at StockNews.com to a “sell” rating in a research report issued on Thursday.

Other research analysts have also recently issued reports about the stock. Needham & Company LLC reissued a “buy” rating and issued a $84.00 price objective on shares of CRISPR Therapeutics in a research note on Wednesday. Rodman & Renshaw initiated coverage on CRISPR Therapeutics in a report on Friday, August 2nd. They set a “buy” rating and a $90.00 price target for the company. Barclays reduced their price objective on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating on the stock in a research note on Wednesday. Truist Financial dropped their target price on shares of CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating for the company in a report on Monday, August 12th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and set a $53.00 price target on shares of CRISPR Therapeutics in a report on Wednesday. Three analysts have rated the stock with a sell rating, eight have given a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $74.94.

CRISPR Therapeutics Price Performance

CRISPR Therapeutics stock opened at $50.72 on Thursday. The firm has a market cap of $4.31 billion, a PE ratio of -15.70 and a beta of 1.67. The stock’s fifty day moving average price is $47.29 and its two-hundred day moving average price is $52.24. CRISPR Therapeutics has a one year low of $43.42 and a one year high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, topping the consensus estimate of ($1.42) by $0.41. The firm had revenue of $0.60 million for the quarter, compared to the consensus estimate of $6.65 million. During the same period in the prior year, the company earned ($1.41) EPS. Sell-side analysts expect that CRISPR Therapeutics will post -5.57 earnings per share for the current fiscal year.

Insider Activity at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 4,293 shares of the firm’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $198,680.04. Following the completion of the transaction, the chief executive officer now directly owns 226,540 shares in the company, valued at $10,484,271.20. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Samarth Kulkarni sold 4,293 shares of the company’s stock in a transaction on Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $198,680.04. Following the sale, the chief executive officer now directly owns 226,540 shares of the company’s stock, valued at approximately $10,484,271.20. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, General Counsel James R. Kasinger sold 1,089 shares of the stock in a transaction on Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $50,398.92. Following the sale, the general counsel now owns 62,597 shares of the company’s stock, valued at approximately $2,896,989.16. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On CRISPR Therapeutics

Several large investors have recently added to or reduced their stakes in CRSP. Capital International Investors grew its position in shares of CRISPR Therapeutics by 27.8% during the 1st quarter. Capital International Investors now owns 7,837,074 shares of the company’s stock worth $534,175,000 after buying an additional 1,702,624 shares during the period. Vanguard Group Inc. increased its stake in CRISPR Therapeutics by 2.9% in the first quarter. Vanguard Group Inc. now owns 1,636,799 shares of the company’s stock valued at $111,564,000 after purchasing an additional 46,148 shares in the last quarter. SR One Capital Management LP bought a new position in shares of CRISPR Therapeutics during the 1st quarter worth about $71,496,000. Dimensional Fund Advisors LP grew its stake in shares of CRISPR Therapeutics by 2.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 950,149 shares of the company’s stock valued at $51,326,000 after buying an additional 19,094 shares during the period. Finally, Farallon Capital Management LLC acquired a new stake in shares of CRISPR Therapeutics in the 2nd quarter valued at about $28,625,000. Institutional investors and hedge funds own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.